Skip to main content
Year archive

PARADIGM BIOPHARMACEUTICALS LIMITED.. — 2022 filings

All 77 regulatory filings released by PARADIGM BIOPHARMACEUTICALS LIMITED.. (PAR) in 2022, sourced directly from the official regulator.

77 Filings
2022 Period
2022 filings (77)
Filing Released Lang
Notification of cessation of securities - PAR 7 pages 30.3KB
Share Issue/Capital Change
2022-12-29 English
Phase 3 OA Trial to Proceed after Formal Safety Review 2 pages 282.1KB
Regulatory Filings
2022-12-27 English
Change of Director's Interest Notice - Rennie 4 pages 185.4KB
Director's Dealing
2022-12-21 English
Change in substantial holding 15 pages 5.6MB
Major Shareholding Notification
2022-12-15 English
PAR Receives Allowance for Key US Patent 2 pages 67.6KB
Regulatory Filings
2022-12-11 English
OA Study Data Accepted for Presentation at OARSI Congress 2 pages 120.4KB
Investor Presentation
2022-12-07 English
Notice of Annual General Meeting-Withdrawal of Resolutions 1
AGM Information
2022-11-28 English
Paradigm AGM Presentation 23 pages 3.7MB
AGM Information
2022-11-28 English
Results of Meeting 2 pages 433.7KB
Declaration of Voting Results & Voting Rights Announcements
2022-11-28 English
Cancel - Application for quotation of securities - PAR 8 pages 28.6KB
Share Issue/Capital Change
2022-11-24 English
Application for quotation of securities - PAR 8 pages 28.8KB
Share Issue/Capital Change
2022-11-24 English
Application for quotation of securities - PAR 8 pages 29.0KB
Share Issue/Capital Change
2022-11-22 English
Paradigm CEO steps down & Appointment of MD 3 pages 220.5KB
Board/Management Information
2022-11-21 English
Paradigm Receives $7.4m R&D Tax Incentive Refund 1
Capital/Financing Update
2022-11-17 English
Notice of release of escrowed securities 1 page 271
Share Issue/Capital Change
2022-11-13 English
MPS-VI Program Accepted for Presentation at WorldSymposium 3 pages 193.7KB
Regulatory Filings
2022-11-10 English
Bell Potter Virtual Healthcare Conference presentation 16 pages 5.9MB
Investor Presentation
2022-11-08 English
Quarterly Activities/Appendix 4C Cash Flow Report 11 pages 437.2KB
Interim / Quarterly Report Q1 2023
2022-10-30 English
Notice of Annual General Meeting/Proxy Form 44 pages 893.4KB
AGM Information
2022-10-27 English
Paradigm Doses First UK Participant in Phase 3 Trial 4 pages 184.9KB
Capital/Financing Update
2022-10-25 English
PAR Reports Successful Primary Endpoint in Phase 2 Trial 10 pages 207.8KB
Regulatory Filings
2022-10-03 English
Trading Halt 2 pages 243.9KB
Regulatory Filings
2022-09-29 English
Successful MPSVI Safety Review and PARA OA 008 Update 4 pages 106.4KB
Capital/Financing Update
2022-09-25 English
Date of AGM & Closing Date for Director Nominations 1
AGM Information
2022-09-22 English
Change of Director's Interest Notice 4 pages 185.5KB
Director's Dealing
2022-09-18 English
Change in substantial holding 2 pages 237.2KB
Major Shareholding Notification
2022-09-18 English
Application for quotation of securities - PAR 8 pages 29.4KB
Share Issue/Capital Change
2022-09-13 English
NOTICE OF RELEASE OF ESCROWED SECURITIES 1 page 273
Share Issue/Capital Change
2022-09-13 English
Application for quotation of securities - PAR 8 pages 29.1KB
Share Issue/Capital Change
2022-09-13 English
Successful Completion of Entitlement Offer 2 pages 225.9KB
Capital/Financing Update
2022-09-12 English
Paradigm Appoints Interim Company Secretary 1 page
Board/Management Information
2022-08-29 English
2022 Annual Report and Appendix 4E 64 pages 3.1MB
Regulatory Filings
2022-08-25 English
Appendix 4G and 2022 Corporate Governance Statement 22 pages 540.0KB
Regulatory Filings
2022-08-25 English
Becoming a substantial holder 15 pages 5.6MB
Major Shareholding Notification
2022-08-22 English
PAR Non-Renounceable Rights Issue Offer Booklet 35 pages 497.3KB
Capital/Financing Update
2022-08-21 English
Cleansing Notice 2 pages 258.8KB
Capital/Financing Update
2022-08-21 English
Application for quotation of securities - PAR 8 pages 29.6KB
Capital/Financing Update
2022-08-18 English
Cleansing Notice 1 page 229.0KB
Capital/Financing Update
2022-08-18 English
Ineligible Shareholder Letter 2 pages 103.4KB
Capital/Financing Update
2022-08-18 English
Paradigm Launches $66M Capital Raising 4 pages 106.0KB
Capital/Financing Update
2022-08-14 English
Investor Presentation - $66m Capital Raise 31 pages 18.2MB
Investor Presentation
2022-08-14 English
Proposed issue of securities - PAR 11 pages 42.3KB
Capital/Financing Update
2022-08-14 English
Cleansing Notice 3 pages 262.5KB
Capital/Financing Update
2022-08-14 English
Letter to Optionholders 2 pages 257.6KB
Capital/Financing Update
2022-08-14 English
Trading Halt 2 pages 221.4KB
Capital/Financing Update
2022-08-10 English
Paradigm provides MPS Clinical Program update 5 pages 122.3KB
Investor Presentation
2022-08-07 English
Quarterly Update and Appendix 4C - quarterly 9 pages 371.2KB
Interim / Quarterly Report Q4 2022
2022-07-27 English
Investor Webinar 2 pages 67.5KB
Investor Presentation
2022-07-14 English
Notification of cessation of securities - PAR 7 pages 29.1KB
Share Issue/Capital Change
2022-07-13 English
Paradigm Partners with NFL Alumni Health for OA Program 3 pages 108.9KB
Capital/Financing Update
2022-07-12 English
Application for quotation of securities - PAR 7 pages 28.1KB
Share Issue/Capital Change
2022-07-11 English
Notification regarding unquoted securities - PAR 12 pages 40.7KB
Share Issue/Capital Change
2022-07-06 English
Paradigm reports global progress in phase 3 study 3 pages 91.4KB
Capital/Financing Update
2022-07-05 English
100% Recruitment in Synovial Fluid Biomarker Trial 3 pages 102.4KB
Regulatory Filings
2022-06-30 English
Paradigm Reports Australian Patent Acceptance 3 pages 91.5KB
Regulatory Filings
2022-06-29 English
NOTICE OF RELEASE OF ESCROWED SECURITIES 1 page 233
Share Issue/Capital Change
2022-06-28 English
Paradigm Receives $8.2m R&D Tax Incentive Refund 1
Regulatory Filings
2022-06-06 English
Paradigm Appoints Experienced US-Based CEO 2 pages 693.6KB
Board/Management Information
2022-05-29 English
Quarterly Update and Appendix 4C - quarterly 8 pages 334.1KB
Interim / Quarterly Report Q3 2022
2022-04-28 English
Paradigm Doses First US Subjects under Phase 3 trial 3 pages 100.6KB
Capital/Financing Update
2022-04-27 English
FDA Grants Paradigm Fast Track Designation For OA 4 pages 111.3KB
Regulatory Filings
2022-04-11 English
UK ethics and regulatory approval for Phase 3 study 2 pages 101.2KB
Regulatory Filings
2022-03-16 English
Clarification of recent analyst report on Patent Protection 3 pages 120.8KB
Regulatory Filings
2022-03-08 English
Change of Director's Interest Notice 4 pages 184.9KB
Director's Dealing
2022-03-08 English
Change in substantial holding 2 pages 237.0KB
Major Shareholding Notification
2022-03-08 English
Half Yearly Report and Accounts 27 pages 3.4MB
Regulatory Filings
2022-02-23 English
Paradigm 1HY22 Key Activity Highlights 5 pages 100.4KB
Interim / Quarterly Report H1 2022
2022-02-23 English
Amended Appendix 4D 4 pages 234.2KB
Interim / Quarterly Report H1 2022
2022-02-23 English
PPS a new adjunct therapy treatment for patients with MPS VI 3 pages 1.9MB
Investor Presentation
2022-02-10 English
Notification regarding unquoted securities - PAR 10 pages 38.6KB
Share Issue/Capital Change
2022-01-31 English
Cleansing Notice 1 page 180.4KB
Regulatory Filings
2022-01-31 English
Change of Director's Interest Notice 2 pages 177.5KB
Director's Dealing
2022-01-31 English
Quarterly Update and Appendix 4C - quarterly 8 pages 343.9KB
Interim / Quarterly Report Q2 2021
2022-01-30 English
Paradigm AGM Presentation 20 pages 7.4MB
AGM Information
2022-01-24 English
Results of Meeting 2 pages 240.4KB
Declaration of Voting Results & Voting Rights Announcements
2022-01-24 English
PARADIGM TREATS FIRST SUBJECTS IN PHASE 3 TRIAL OF ZILOSUL 4 pages 111.5KB
Regulatory Filings
2022-01-12 English
Paradigm to present at the J.P Morgan Healthcare Conference 17 pages 16.0MB
Investor Presentation
2022-01-11 English